Literature DB >> 25647225

Ipilimumab-associated bilateral optic neuropathy.

Oliver L Yeh1, Courtney E Francis.   

Abstract

Ipilimumab is a novel monoclonal antibody targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) receptor that has been shown to improve survival in metastatic melanoma. Previous case reports have documented its association with drug-induced uveitis. We report a patient who developed bilateral optic neuropathy with disc edema while taking this medication.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25647225     DOI： 10.1097/WNO.0000000000000217

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN： 1070-8022            Impact factor:   3.042


  19 in total

Review 1.  Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.

Authors:  Peter Chei-Way Pan; Aya Haggiagi
Journal:  Curr Oncol Rep       Date:  2019-11-27       Impact factor: 5.075

Review 2.  Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.

Authors:  Shannon K Quirk; Anna K Shure; Devendra K Agrawal
Journal:  Transl Res       Date:  2015-06-11       Impact factor: 7.012

Review 3.  Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

Authors:  Yu-Wen Zhou; Qian Xu; Yan Wang; Ruo-Lan Xia; Ji-Yan Liu; Xue-Lei Ma
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

4.  Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity.

Authors:  Aditya Rali; Ye Huang; Steven Yeh
Journal:  Int Ophthalmol Clin       Date:  2022-06-22

Review 5.  Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.

Authors:  Shruthi Harish Bindiganavile; Nita Bhat; Andrew G Lee; Dan S Gombos; Nagham Al-Zubidi
Journal:  J Immunother Precis Oncol       Date:  2021-02-25

Review 6.  Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Authors:  Christophoros Astaras; Rita de Micheli; Bianca Moura; Thomas Hundsberger; Andreas F Hottinger
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-01       Impact factor: 5.081

Review 7.  Neuro-ophthalmic side effects of molecularly targeted cancer drugs.

Authors:  M T Bhatti; A K S Salama
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

8.  Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.

Authors:  Jonathan E Lu; Jessica R Chang; Jesse L Berry; Gino K In; Sandy Zhang-Nunes
Journal:  Int Ophthalmol Clin       Date:  2020

9.  Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer.

Authors:  Kenji Takada; Keiichi Fujiwara; Eri Ando; Kiriko Onishi; Tadahiro Kuribayashi; Sho Mitsumune; Yuki Takigawa; Hiroaki Matsuura; Hiromi Watanabe; Kenichiro Kudo; Akiko Sato; Ken Sato; Takuo Shibayama
Journal:  Case Rep Oncol       Date:  2021-06-09

10.  Ocular adverse events in PD-1 and PD-L1 inhibitors.

Authors:  LeAnne Young; Shanda Finnigan; Howard Streicher; Helen X Chen; James Murray; H Nida Sen; Elad Sharon
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.